Clinical Scorecard: Could Statins Help Prevent Glaucoma?

At a Glance

Key Highlights

• In matched cohorts of 210,701 statin users and 210,701 non-users, five-year OAG incidence was 2.3% and 2.6%, respectively (HR 0.85).
• The association with lower OAG incidence persisted at 10 years, with a smaller relative reduction (HR 0.90).
• Among patients with established OAG, statin use was associated with lower five-year risks of incisional surgery (36%), MIGS (55%), SLT (60%), and topical ocular hypotensive prescriptions (11%); corresponding 10-year reductions were 32%, 46%, 51%, and 12%.
• Atorvastatin and rosuvastatin were consistently associated with reduced incidence and treatment escalation; findings for simvastatin and pravastatin were less consistent.
• The observational design and lack of detailed IOP, visual-field, and optic-nerve imaging data prevent conclusions about causality or direct disease progression.

Guideline-Based Recommendations

Diagnosis

• The study evaluated OAG incidence using electronic health records; it did not provide diagnostic recommendations.

Management

• The article identifies IOP lowering as the principal strategy for glaucoma management.
• The researchers state that prospective randomized trials are needed to determine whether statins reduce glaucoma onset or progression.

Monitoring & Follow-up

• The database lacked detailed IOP measurements, visual fields, and optic nerve imaging, limiting direct assessment of glaucoma progression.
• Treatment escalation was used as an indirect indicator of disease severity.

Risks

• The retrospective observational design precludes conclusions that statins caused the observed associations.
• The article does not establish statins as an adjunctive glaucoma therapy.

Patient & Prescribing Data

Incidence analysis: 210,701 statin users aged over 40 matched with 210,701 non-users. Established-OAG analysis: 29,598 individuals in each cohort.

Among patients with established OAG, statin use was associated at five years with lower risks of incisional glaucoma surgery (36%), MIGS (55%), SLT (60%), and topical ocular hypotensive prescriptions (11%). At 10 years, the corresponding reductions were 32%, 46%, 51%, and 12%. These are observational associations, not prescribing recommendations.

Clinical Best Practices

• The study reports associations between statin use and lower OAG incidence and treatment escalation; its observational design does not establish a causal effect.
• The study used treatment escalation as an indirect indicator of disease severity because detailed clinical measures of progression were unavailable.
• The researchers state that prospective randomized trials are needed to establish whether statins affect glaucoma onset or progression.

Related Resources & Content

• British Journal of Ophthalmology study; the provided source does not include the article title, authors, or URL.